Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
21-40 of 1,743 trials

HER2 Status in Solid Tumors: [68Ga]Ga-ABY-025 PET Study

We are investigating a new PET imaging method to measure HER2 status in patients with low HER2 breast cancer. This study aims to see if it can help better identify tumor characteristics and improve treatment planning.

Breast CancerGastro-esophageal Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Glioblastoma: Early Intensified Treatment with Temozolomide

We are studying whether starting chemotherapy earlier with temozolomide helps adults with glioblastoma live longer compared to standard treatment. The trial also examines safety and treatment effectiveness.

Glioblastoma>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesNeurologyOncology

Multiple Myeloma: Isatuximab and Lenalidomide Study

We are comparing two treatment plans for newly diagnosed low-risk multiple myeloma patients to see which is more effective in reducing cancer cells. This study aims to understand the best approach for long-term patient health.

Multiple Myeloma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteHematologyOncology

Marstacimab for Severe Hemophilia A and B

We are studying the long-term safety and effectiveness of marstacimab in people aged 1 to 75 with severe hemophilia A or B, with or without inhibitors. This research aims to improve treatment options for managing this condition.

Haemophilia>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematology

Myelodysplastic Syndrome: Oral Azacitidine Study

We are studying whether Oral Azacitidine, combined with best supportive care, is more effective than a placebo for patients with low- or intermediate-risk MDS. The goal is to see if it improves blood counts and reduces the need for blood transfusions.

Myelodysplastic Syndromes (MDS)>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesHematology

Fabry Disease: Migalastat for Kidney Impairment

We are studying the safety and how the body processes migalastat in people with Fabry disease and severe kidney impairment on dialysis. This research aims to ensure the right dosing for these patients.

Fabry Disease>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyInternal MedicineNephrology

Advanced Solid Tumors: M9140 Treatment Study

We are testing a new drug called M9140 for people with advanced solid tumors. The goal is to see if it can improve treatment outcomes compared to current therapies.

Advanced Solid Tumors>2 yearsSafety phase (I)Oncology

MOG Antibody Disease: Azathioprine Study

We are testing whether azathioprine can help prevent relapses in adults with MOG antibody-associated disease after their first attack. The study also looks at safety and quality of life for participants.

Anti-Myelin-Associated Glycoprotein Antibodies Positive>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesPartially RemoteInternal MedicineNeurology

Prostate Cancer: Lutetium-177 vs. Standard Treatments

We are comparing a new treatment called Lutetium-177 with standard medications for men with metastatic hormone-sensitive prostate cancer. The goal is to see which option better delays disease progression and improves survival.

Prostate Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteOncologyUrology

Individualized Immunotherapy for Early-Stage Hodgkin Lymphoma

We are testing a new personalized treatment using tislelizumab for adults with early-stage unfavorable classical Hodgkin lymphoma. The goal is to see if this approach improves treatment outcomes and is safe for patients.

Early-Stage Unfavorable Classical Hodgkin Lymphoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Prostate Medication and Gut Health Study

We are investigating how prostate treatments affect gut bacteria and how these bacteria may influence treatment responses in men with BPH and prostate cancer.

Prostate CancerBenign Prostate Hyperplasia>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineUrology

MRSA Treatment: Povidone Iodine Nasal Kit

We are evaluating a nasal decolonization kit with povidone iodine for patients with MRSA. The study aims to see how well it reduces MRSA levels and how patients feel about using it.

MRSA Infection>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesDermatologyInfectious Diseases

Hepatocellular Carcinoma: New Vaccine with Atezolizumab and Bevacizumab

We are studying a new cancer vaccine combined with two existing treatments for patients with unresectable liver cancer. The goal is to see if this combination improves survival and quality of life.

Non-resectable Hepatocellular Carcinoma>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesHepatologyInternal MedicineOncology

Immunotherapy for Early dMMR Rectal Cancer

We are studying the effects of nivolumab and ipilimumab in patients with stage 1-3 dMMR rectal cancer. The goal is to see how effective and tolerable this treatment is.

Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

Oligometastatic Solid Cancer: SBRT with ATRA Support

We are studying a new radiation therapy combined with a drug to support the immune system in patients with oligometastatic solid cancer. This trial aims to evaluate safety and how well the treatment works.

Oligometastatic Solid Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementOncology

Geographic Atrophy: JNJ-81201887 Treatment Study

We are examining the long-term safety and tolerability of JNJ-81201887 for people with geographic atrophy from age-related macular degeneration. This study follows participants from earlier trials to gather more information.

Geographic Atrophy>2 yearsEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteOphthalmology

Advanced Breast Cancer: Ribociclib Study

We are examining how well Ribociclib works for patients with advanced breast cancer and what factors may affect its effectiveness. The study also looks at quality of life and any side effects experienced during treatment.

Hormone Receptor Positive HER2 Negative Breast Cancer>2 yearsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Morphine Study in Obesity and Sleep Apnea Patients

We are investigating how obesity and obstructive sleep apnea influence the effects of morphine for pain relief. This research aims to improve pain management for patients, especially those having bariatric surgery.

Obesity Surgery>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementEndocrinologyInternal MedicineOrthopedics and TraumatologyOtolaryngologyPsychiatry

Multiple Myeloma: Anti-BCMA CAR T Cell Therapy

We are studying a new CAR T cell treatment for patients with relapsed or refractory Multiple Myeloma. The trial aims to evaluate its safety and effectiveness in improving patient outcomes.

Relapsed/Refractory Multiple Myeloma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Acute Myeloid Leukemia: New Treatments for Children and Adolescents

We are exploring different therapies for children and adolescents with acute myeloid leukemia to see if they improve survival and treatment outcomes. This includes testing new drugs alongside standard chemotherapy.

Acute Myeloid Leukemia>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyPediatrics